HUP0401599A2 - Elnyújtott kibocsátású új orális adagolási forma - Google Patents
Elnyújtott kibocsátású új orális adagolási formaInfo
- Publication number
- HUP0401599A2 HUP0401599A2 HU0401599A HUP0401599A HUP0401599A2 HU P0401599 A2 HUP0401599 A2 HU P0401599A2 HU 0401599 A HU0401599 A HU 0401599A HU P0401599 A HUP0401599 A HU P0401599A HU P0401599 A2 HUP0401599 A2 HU P0401599A2
- Authority
- HU
- Hungary
- Prior art keywords
- active ingredient
- oral dosage
- dosage form
- blood plasma
- plasma concentration
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 238000013265 extended release Methods 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 5
- 210000002381 plasma Anatomy 0.000 abstract 3
- 230000036470 plasma concentration Effects 0.000 abstract 3
- 229940122081 5 Hydroxytryptamine receptor agonist Drugs 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000952 serotonin receptor agonist Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya egy 5-hidroxi-triptamin receptor agonista,részleges agonista vagy antagonista hatóanyagot legalább egy gélképzőpolimerrel és adott esetben egyéb segédanyagokkal együtt tartalmazóelnyújtott kibocsátású orális adagolási forma és eljáráselőállítására. A hatóanyag előnyösen a vízben jól oldódó (R)-3-(N,N-diciklobutil-amino)-8-fluor-3,4-dihidro-2H-l-benzopirán-5-karboxamidszabad bázis, gyógyszerészetileg elfogadható sói és/vagy hidrátjaivagy szolvátjai formájában. A találmány szerinti új orális adagolásiforma a hatóanyag olyan vérplazma-koncentráció profilját biztosítja,amelynél a vérplazma-koncentrációban nem következik be gyors kezdetiemelkedés; a maximális vérplazma-koncentráció eléréséhez szükséges időlegalább ötször olyan hosszú, mintha az illető hatóanyagot orálisan,vizes oldata alakjában alkalmaznánk; a hatóanyag tartózkodási idejelegalább háromszor olyan hosszú, mintha a hatóanyagot orálisan, vizesoldata alakjában, éhgyomorra adnánk be. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102887A SE0102887D0 (sv) | 2001-08-29 | 2001-08-29 | New formulation |
| PCT/SE2002/001541 WO2003017983A1 (en) | 2001-08-29 | 2002-08-28 | A new extended release oral dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401599A2 true HUP0401599A2 (hu) | 2004-11-29 |
| HUP0401599A3 HUP0401599A3 (en) | 2007-03-28 |
Family
ID=20285178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401599A HUP0401599A3 (en) | 2001-08-29 | 2002-08-28 | Extended release oral dosage form |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040197404A1 (hu) |
| EP (1) | EP1423099A1 (hu) |
| JP (1) | JP2005504052A (hu) |
| KR (1) | KR20040032977A (hu) |
| CN (1) | CN1549705A (hu) |
| BR (1) | BR0212167A (hu) |
| CA (1) | CA2457341A1 (hu) |
| HU (1) | HUP0401599A3 (hu) |
| IL (1) | IL160371A0 (hu) |
| MX (1) | MXPA04001805A (hu) |
| NO (1) | NO20040857L (hu) |
| SE (1) | SE0102887D0 (hu) |
| WO (1) | WO2003017983A1 (hu) |
| ZA (1) | ZA200401547B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2755273T3 (es) * | 2004-12-03 | 2020-04-22 | Merck Sharp & Dohme | Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación |
| CN101304764B (zh) * | 2005-11-11 | 2012-12-05 | 旭化成化学株式会社 | 控释固体制剂 |
| GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| US20100069390A1 (en) | 2008-09-05 | 2010-03-18 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
| KR20140090663A (ko) * | 2011-11-07 | 2014-07-17 | 디아크론 파마슈티칼스, 인코포레이티드 | 직접 트롬빈 억제제의 연장 방출성 제형 |
| AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
| US10071058B2 (en) * | 2012-03-07 | 2018-09-11 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
| US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
| GB8624213D0 (en) * | 1986-10-09 | 1986-11-12 | Sandoz Canada Inc | Sustained release pharmaceutical compositions |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| SE510305C2 (sv) * | 1997-05-30 | 1999-05-10 | Astra Ab | Nytt salt |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
-
2001
- 2001-08-29 SE SE0102887A patent/SE0102887D0/xx unknown
-
2002
- 2002-08-28 KR KR10-2004-7002920A patent/KR20040032977A/ko not_active Application Discontinuation
- 2002-08-28 IL IL16037102A patent/IL160371A0/xx unknown
- 2002-08-28 WO PCT/SE2002/001541 patent/WO2003017983A1/en not_active Application Discontinuation
- 2002-08-28 CN CNA028168712A patent/CN1549705A/zh active Pending
- 2002-08-28 MX MXPA04001805A patent/MXPA04001805A/es unknown
- 2002-08-28 CA CA002457341A patent/CA2457341A1/en not_active Abandoned
- 2002-08-28 EP EP02763155A patent/EP1423099A1/en not_active Withdrawn
- 2002-08-28 HU HU0401599A patent/HUP0401599A3/hu unknown
- 2002-08-28 JP JP2003522503A patent/JP2005504052A/ja active Pending
- 2002-08-28 US US10/488,125 patent/US20040197404A1/en not_active Abandoned
- 2002-08-28 BR BR0212167-0A patent/BR0212167A/pt not_active IP Right Cessation
-
2004
- 2004-02-25 ZA ZA200401547A patent/ZA200401547B/en unknown
- 2004-02-26 NO NO20040857A patent/NO20040857L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SE0102887D0 (sv) | 2001-08-29 |
| KR20040032977A (ko) | 2004-04-17 |
| EP1423099A1 (en) | 2004-06-02 |
| JP2005504052A (ja) | 2005-02-10 |
| ZA200401547B (en) | 2004-11-17 |
| HUP0401599A3 (en) | 2007-03-28 |
| US20040197404A1 (en) | 2004-10-07 |
| MXPA04001805A (es) | 2004-07-08 |
| NO20040857L (no) | 2004-04-19 |
| IL160371A0 (en) | 2004-07-25 |
| CN1549705A (zh) | 2004-11-24 |
| BR0212167A (pt) | 2004-07-20 |
| CA2457341A1 (en) | 2003-03-06 |
| WO2003017983A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
| WO2004026256A3 (en) | Sustained-release opioid formulations and methods of use | |
| EE05383B1 (et) | Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon | |
| HUP0101411A2 (hu) | 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
| DK1414451T3 (da) | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist | |
| HUP0201877A2 (hu) | Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák | |
| HUP0400475A2 (hu) | Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| IT1271495B (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| HUP0000138A2 (hu) | Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények | |
| EE05022B1 (et) | Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat | |
| DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| IS6892A (is) | Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn | |
| HUP0301305A2 (hu) | Dopamin D2/D3 receptor agonisták alkalmazása fibromialgia kezelésére szánt gyógyászati készítmények előállítására | |
| HUP9903732A2 (hu) | cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására | |
| EP0966966A3 (en) | Nefazodone dosage form | |
| HUP0401599A2 (hu) | Elnyújtott kibocsátású új orális adagolási forma | |
| CY1109939T1 (el) | Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου | |
| BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
| HUP0003836A2 (hu) | Lazofoxifent tartalmazó gyógyszerkészítmények | |
| DE50005082D1 (de) | Verfahren zu Herstellung von PULVERFÖRMIGEn SOLUBILISATIONSHILFSSTOFFEn FÜR FESTE PHARMAZEUTISCHE DARREICHUNGSFORMEN | |
| HUP0402358A2 (hu) | Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására | |
| HUP0402080A2 (hu) | Kannabinoid receptor agonisták alkalmazása gastrooesophagealis reflux betegség kezelésére szolgáló gyógyszer előállítására | |
| TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |